Lantheus Holdings, Inc. Cost of Revenue
Lantheus Holdings, Inc. (LNTH) reported Cost of Revenue of $168.49 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-20.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2019-02-20
- Lantheus Holdings, Inc. cost of revenue for fiscal 2018 was $168.49M, a 0.45% decline from fiscal 2017.
- Lantheus Holdings, Inc. cost of revenue for fiscal 2017 was $169.24M, a 3.15% increase from fiscal 2016.
- Lantheus Holdings, Inc. cost of revenue for fiscal 2016 was $164.07M.
| Period end | Cost of Revenue 12 month |
|---|---|
| 2018-12-31 | $168.49M 10-K · filed 2019-02-20 |
| 2017-12-31 | $169.24M 10-K · filed 2019-02-20 |
| 2016-12-31 | $164.07M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |